Key result
CRP apheresis reduces infarct size by ~5% and improves LVEF in high-CRP STEMI patients.
Why the study?
It was unknown whether the early clinical benefits of CRP apheresis on cardiac damage after STEMI are sustained once wound healing is complete.
Does C-reactive protein apheresis improve myocardial infarct size and left ventricular function in patients with ST-Elevation Myocardial Infarction?
Does C-reactive protein apheresis improve myocardial infarct size and left ventricular function in patients with ST-Elevation Myocardial Infarction?
Mean Difference: -5.4
p-value: p=0.05
CRP apheresis after STEMI may provide sustained improvements in infarct size and left ventricular function specifically in patients with high CRP production.
No takes yet. Share an insight, caveat, or question.
Premature for clinical adoption post-STEMI; leaves open whether CRP reduction improves infarct size or ventricular function in randomized trials.
Skarabis et al. (2022) studied Acute Myocardial Infarction (STEMI) (n=66). C-reactive protein (CRP) apheresis vs. Control group was evaluated on Myocardial infarct size (IS) (MD -5.4%, p=0.05). In STEMI patients with high CRP production, CRP apheresis significantly reduced myocardial infarct size (-5.4%; p=0.05) and improved left ventricular ejection fraction (+6.4%; p=0.03) at 88 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: